SCHEMBL20264085

SCHEMBL20264085

COc1ccc(CN2C(=O)[C@@H](NC(=O)OC(C)(C)C)CSc3ccc(C(=O)O)cc32)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 1/20 0.44
▸ XIAP P98170 2/20 0.44
▸ MAPT P10636 4/20 0.42
▸ SRC P12931 4/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ NPY1R P25929 1/20 0.40
▸ F7 P08709 1/20 0.40
▸ F3 P13726 1/20 0.40
▸ HDAC3 O15379 1/20 0.40
▸ HDAC4 P56524 1/20 0.40
▸ HDAC1 Q13547 1/20 0.40
▸ HDAC7 Q8WUI4 1/20 0.40
▸ HDAC2 Q92769 1/20 0.40
▸ HDAC10 Q969S8 1/20 0.40
▸ HDAC11 Q96DB2 1/20 0.40
▸ HDAC8 Q9BY41 1/20 0.40
▸ HDAC6 Q9UBN7 1/20 0.40
▸ HDAC9 Q9UKV0 1/20 0.40
▸ HDAC5 Q9UQL6 1/20 0.40
▸ GFER P55789 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31375587 0.98 XIAP (0.46) NPC1XIAPMAPTSRCSMN1; SMN2
SCHEMBL20279843 0.93 TP53 (0.42) NPC1XIAPMAPTSRCSMN1; SMN2
SCHEMBL29796998 0.92 XIAP (0.46) NPC1XIAPMAPTSRCNPY1R
SCHEMBL26961658 0.92 XIAP (0.46) NPC1XIAPMAPTSRCNPY1R
SCHEMBL20264228 0.92 XIAP (0.48) NPC1XIAPMAPTSRCNPY1R
SCHEMBL29796955 0.91 NPC1 (0.45) NPC1XIAPMAPTSMN1; SMN2NPY1R
SCHEMBL20264153 0.91 NPC1 (0.45) NPC1XIAPMAPTSMN1; SMN2NPY1R
SCHEMBL20280018 0.91 NPC1 (0.45) NPC1XIAPMAPTSRCSMN1; SMN2
SCHEMBL31628063 0.91 XIAP (0.42) NPC1XIAPMAPTSRCSMN1; SMN2
SCHEMBL20263960 0.91 NPC1 (0.42) NPC1XIAPMAPTSRCNPY1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10472341-B2 Bicyclic tetrahydrothiazepine derivatives useful for the treatment of neoplastic and/or infectious diseases APEIRON BIOLOGICS AG (AT) 2019-11-12 — — US disclosed
EP-3265463-B1 BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES USEFUL FOR THE TREATMENT OF NEOPLASTIC AND/OR INFECTIOUS DISEASES APEIRON BIOLOGICS AG (AT) 2018-12-19 — — EP disclosed
US-20180170888-A1 BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES USEFUL FOR THE TREATMENT OF NEOPLASTIC AND/OR INFECTIOUS DISEASES APEIRON BIOLOGICS GMBH (AT) 2018-06-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10472341-B2 Bicyclic tetrahydrothiazepine derivatives useful for the treatment of neoplastic and/or infectious diseases CCNT2, HRH4, HRH3 NPC1 563/4885XIAP 3498/4885MAPT 2443/4885
US-20180170888-A1 BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES USEFUL FOR THE TREATMENT OF NEOPLASTIC AND/OR INFECTIOUS DISEASES CCNT2, HRH4, HRH3 NPC1 563/4885XIAP 3498/4885MAPT 2443/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback